Given the high rate of Candida colonization in psoriatic patients and the potential role of Candida in psoriasis onset, the use of PDE-4 inhibitors may represent an effective therapeutic approach for better management of sub-clinical risk of candidiasis in those patients. This evidence concerns the gene PDE4A and Candidiasis, Invasive.